The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication

摘要

Over the last 2 decades, there has been increasing widespread use of second-generation antipsychotic (SGA) medications in nonpsychotic pediatric populations in the United States and Europe.~(1)~(-3) As the ubiquity of SGA drugs in treatment plans for these children and adolescents grows, so does the controversy surrounding them.